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Low Birth Weight (LBW) is a surrogate for fetal undernutrition and is associated with
impaired nephron development in utero. In this study, we investigate whether having been
born LBW and/or small for gestational age (SGA) predict progression to ESRD in IgA
nephropathy (IgAN) patients.
Study Design
Retrospective registry-based cohort study.
Settings & Participants
TheMedical Birth Registry has recorded all births since 1967 and the Norwegian Renal Reg-
istry has recorded all patients with ESRD since 1980. Based on data from the Norwegian Kid-
ney Biopsy Registry we included all patients diagnosed with IgAN in Norway from 1988–
2013. These registries were linked and we analysed risk of progression to ESRD associated
with LBW (defined as birth weight less than the 10th percentile) and/or SGA (defined as birth
weight less than the 10th percentile for gestational week) by Cox regression statistics.
Results
We included 471 patients, of whom 74 developed ESRD. As compared to patients without
LBW, patients with LBW had a hazard ratio (HR) of 2.0 (95% confidence interval 1.1–3.7)
for the total cohort, 2.2 (1.1–4.4) for males and 1.3 (0.30–5.8) for females. Corresponding
HRs for SGA were 2.2 (1.1–4.2), 2.7 (1.4–5.5) and 0.8 (0.10–5.9). Further analyses showed
that as compared to patients with neither LBW nor SGA, patients with either SGA or LBW
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did not have significantly increased risks (HRs of 1.3–1.4) but patients who were both LBW
and SGA had an increased risk (HR 3.2 (1.5–6.8).
Limitation
Mean duration of follow-up only 10 years and maximum age only 46 years.
Conclusion
Among IgAN patients, LBW and/or SGA was associated with increased risk for progression
to ESRD, the association was stronger in males.
Introduction
Brenner hypothesized in 1988 that adverse intrauterine environment, for example due to placental
insufficiency or maternal malnutrition, was associated with impaired nephron development and
increased risk of hypertension and progressive kidney disease in adult life[1]. Low birth weight
(LBW) is the most accessible marker of adverse intrauterine environment[1] and studies have
shown strong associations with fewer and larger glomeruli[2,3], increased risk of hypertension
[4,5], albuminuria [6,7] and progressive chronic kidney disease[8,9]. It is possible that SGA, defined
as low birth weight for gestational age, is a better marker for adverse intrauterine environment and
studies have shown associations with lower GFR [10,11]. Previous studies have suggested LBW,
SGA and preterm birth to be associated with reduced estimated and measured GFR [12–14].
IgA nephropathy (IgAN) is the most frequently occurring primary idiopathic glomerulone-
phritis worldwide [15–17]. The clinical phenotype of IgAN range from stable and asymptom-
atic to chronic and progressive renal failure [18–20] and several studies have investigated
clinical and histopathological variables as risk factors for progressive disease [21–25]. Due to
its chronic course it is possible to look upon IgAN as a model disease for chronic kidney disease
in general and the advantages of this might be that IgAN patients generally are younger, have
fewer confounding comorbidities while on the other hand having a high rate of progressive dis-
ease. Specifically, for the investigation of the Brenner hypothesis, better access to birth related
data in these younger patients is also of benefit. As described above, LBWmight be a risk factor
for progressive IgAN as LBW is associated with fewer and larger glomeruli [2,3]. Indeed a pre-
vious study by Tsuboi et al demonstrated that lower glomerular density predicted the long-
term prognosis of IgAN[26]. Also in support of this, low birth weight was associated with
higher rates of progressive disease in a small study of children with IgAN[27]. More and larger
studies are however needed to explore this further.
In the present study we used data from Norwegian Registries and analyzed whether adverse
birth-weight related variables are associated with development of end-stage renal disease
(ESRD) in patients diagnosed with IgAN in Norway in the period 1988–2013. We first ana-
lyzed whether LBW predicted progression to ESRD, but also analyzed the effects of SGA and
preterm birth, and combinations of these factors. Our main hypothesis was that LBW and SGA
predict progression to ESRD, in line with the Brenner hypothesis.
Material and Methods
Since 1967, the Medical Birth Registry of Norway has registered extensive medical data on all
births in Norway (total population of 5.1 million) [28]. The form is completed by the attending
midwife and doctor. Since 1980, the Norwegian Renal Registry has registered data on all
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patients in Norway who develop ESRD (defined as starting chronic dialysis treatment or
undergoing renal transplantation). The Norwegian Kidney Biopsy Registry has registered clini-
cal and morphologic data for all patients who have had a kidney biopsy performed in Norway
since 1988. All kidney biopsies in this study were evaluated by an experienced nephropatholo-
gist. The data from all registries were available until December 2013 and data were linked using
the 11-digit unique national identification number.
We included all patients diagnosed with IgA nephropathy in the Norwegian Kidney Biopsy
Registry between 1988 and 2013 and who were born in Norway after 1967 and had their birth
data registered in the Medical Birth Registry. The study was approved by the Regional Ethics
Committee of Norway. Patient records/information was anonymized and de-identified prior to
analysis. This investigation abides to Declaration of Helsinki.
Exposure Variables
LBW was defined as birth weight less than the 10th percentile for gender (2930g for male;
2690g for female). Based on total data from the Medical Birth Registry, different cut-offs were
tested in separate analyses (For male and female gender respectively the 25th percentile was
defined as 3233g and 3050g, the 20th percentile as 3168g and 2960g, the 15th percentile as
3070g and 2910g and the 7.5th percentile as 2860g and 2640g). From 1967 through 1998, gesta-
tional age was based on the last menstrual period and from 1999 onward on routine ultrasono-
graphic examination in gestational weeks 17 through 20. Preterm birth was defined as a
gestational age less than 37 weeks. Based on national data on birth weight, gestational week,
gender and plurality, a z-score denoting standard deviation from mean of birth weight for each
week of gestational age was calculated for each patient by the Medical Birth Registry [29,30].
Small for gestational age (SGA) was defined as birth weight less than the 10th percentile for ges-
tational week in the study population (defined by z-score less than -1.2900 for male and
-1.5280 for female gender). In separate analyses, different cut-offs for birth weight for gesta-
tional age (defined by z-score), separately for gender, were tested. The respective z-scores for
males and females for the 25th percentile were defined as -0.7400 and -0.9600, for 20th percen-
tile as -0.8680 and -1.1620, for 15th percentile as -1.1120 and -1.3360 and for 7.5th as -1.5000
and -1.6620. Maternal preeclampsia was defined as increased BP and proteinuria after 20
weeks of gestation (BP140/90)[31].
Recorded standard clinical and laboratory tests were performed at the time of kidney biopsy.
Estimated glomerular filtration rate (eGFR) was calculated using the IDMS-traceable CKD-EPI
equation [32] using the serum creatinine values (unit micromoles/L, converted to mg/L for
eGFR calculation) recorded at the time of biopsy (All patients were assumed to be of white
race). The CKD-EPI is calculated as; eGFR = 141 x Min (Serum Creat/k,1)α x Max(Serum
Creat/k,1)-1.209 x 0.993Age x 1.018 (if female); where k = 0.7 for females and 0.9 for males, α =
0.329 for females and 0.411 for males [33]. For patients who had a kidney biopsy performed
before year 2005, their serum creatinine levels were reduced by 5% to standardize them to
IDMS-traceable levels [33]. For use in the present study we defined three categories of eGFR
as:>60, 30–60 and<30 ml/min/1.73m2. Proteinuria had been registered as grams per 24 h,
grams per litre and milligrams per millimole creatinine and as stix results. Estimates for pro-
teinuria per 24h were calculated as described previously [34], three categories of<1, 1–3 and
> = 3 grams/24h were used in the analyses. Systolic blood pressure was reported in three cate-
gories based on blood pressure level:<140, 140–159 or> = 160 mmHg, cut-offs for diastolic
BP were 90 and 100 mmHg. The following histopathological parameters were used; proportion
of sclerosed glomeruli, proportion of glomeruli with crescents (cellular or fibrocellular), grade
of interstitial fibrosis (categorized as mild, moderate or severe if the fibrosis involved<25%,
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25–50% or more than 50% of the cortical area respectively) and grade of tubular atrophy which
was (categorized as mild, moderate or severe if the tubular atrophy involved<25%, 25–50% or
more than 50% of the cortical area). Treatment data (type of medications, dose and duration)
were not available, see discussion for a description of standard treatment in Norway.
Outcome Variables
The outcome was development of ESRD defined as the date of starting chronic dialysis treat-
ment or undergoing renal transplantation. Individuals who did not develop ESRD were fol-
lowed until December 31, 2013.
Statistical Analyses
Data were analysed in a cohort design with birth-weight related variables as exposure and
ESRD as outcome variables. Hazard ratio estimates associated with selected risk factors for
ESRD were obtained by Cox regression analyses. Assumptions of proportional hazard were
tested by log-minus-log plots and the assumptions were met. Analyses were performed for the
total cohort, but also separately for male and female. Associations between birth weight related
variables and clinical and histopathological variables at time of biopsy were investigated but in
the present paper we did not focus on the effects of the latter variables on risk of ESRD as these
have been thoroughly described previously[35]. Due to low number of endpoints, we chose to
only perform adjusted analyses for eGFR. The analyses were performed with the statistical
package SPSS 21 (SPSS, Chicago, IL). Unless otherwise noted, values are reported as means
(standard deviation) or hazard ratio estimates (95% confidence intervals). P-values< 0.05
were considered statistically significant, and all tests were two tailed.
Results
A total of 471 patients (70.8% males) were included in our study, of whom 74 (15.7%) devel-
oped ESRD. Mean age at biopsy was 23.8 (7.7) years, mean duration of follow-up after biopsy
was 10.3 (6.7) (range 0.08–25.8) years, mean age at ESRD was 29.3 (7.0) years and mean age at
end of follow-up for those who did not develop ESRD was 35.1 (8.1) years. Of the included
patients, 10.2% were categorized as having had LBW and 9.6% as SGA.
At the time of kidney biopsy, IgAN patients born with LBW or SGA had comparable clinical
and pathological characteristics as those born without LBW (Table 1). When the same analysis
was repeated gender-wise, males had significantly higher systolic blood pressure (132 mmHg
vs 123 mmHg, p-value< 0.001) and diastolic blood pressure (80 mmHg vs 76 mmHg, p-value
0.01) than females. There was no gender difference observed in the other clinicopathological
characteristics, including estimated GFR. As expected, patients born with LBW or SGA more
often were born preterm, patients born SGA also had a statistically significant higher likelihood
of being born in a preeclamptic pregnancy.
In separate analyses of male and female patients, SGA was significantly associated with
higher urinary protein excretion (3.0 vs 1.9 gram/24h; p = 0.04) in males but not females. Anal-
yses for other clinical and histopathological variables at the time of biopsy showed no signifi-
cant associations. Comparing clinicopathological characteristics in Table 1 between those with
both LBW and SGA to those with neither of them showed no significant differences.
As expected from previous studies [35], patients who developed ESRD had lower eGFR,
higher blood pressure, higher urinary protein excretion and higher grade of interstitial fibrosis
or tubular atrophy and had a higher risk of developing ESRD. The present study does not focus
on these data, but for completeness, details are given in S1 Table and S2 Table.
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Birth weight related variables and the risk of developing ESRD
Compared to patients with birth weight above the 10th percentile, LBW was significantly asso-
ciated with higher risk of developing ESRD, HR 2.0 (95% CI 1.1–3.7; p = 0.03) (Table 2). Simi-
larly, SGA was also significantly associated with ESRD; HR 2.2 (1.2–4.2); p = 0.02).
When the analyses were done separately for male and female patients, both SGA and LBW
remained statistically significant predictors of ESRD in males, but there was no excess risk in
females (Table 2 and Figs 1 and 2). After adjustments for eGFR, neither LBW nor SGA were
significantly associated with risk of ESRD. A similar analysis for preterm birth, showed a non-
significant higher risk of ESRD for the total cohort and for both gender subgroups.
To explore these associations further, we analyzed risk of developing ESRD by decremental
birth weight and birth weight according to the gestational age (Table 3). In these analyses we
categorized birth weight and birth weight for gestational age below 25th, 20th, 15th, 10th and
7.5th percentile cut-offs. For birth weight, the hazard ratio was statistically significant for the
15th and 10th percentile but not significant for the 7.5th percentile. For birth weight for gesta-
tional age, the hazard ratio increased with lower cut-off and was statistically significant for
the 10th and 7.5th percentile cut-off, the hazard ratio was highest when using the 7.5th percen-
tile. A separate analysis using a cut-off of 2.5 kg (conforming to the WHO global LBW thresh-
old) showed hazard ratio of 1.0 (0.31–3.1) for the total cohort, 1.24 (0.30–5.1) for males and
0.81 (0.11–6.1) for females; however, analysis using this cut-off value was limited by the low
number of patients (only 20 patients had birth weight less than 2.5 kg, of whom 3 developed
ESRD).
Table 1. Cohort characteristics at the time of IgAN diagnosis stratified by Low BirthWeight and Small for Gestational Age, Norway 1967–2013.
LBW SGA
Clinicopathological characteristics No Yes No Yes
N (%) 423 48 (10.2) 405 45(9.6)
N (%) male 298 (70.4) 34 (70.8) 283 (69.9) 32 (71.1)
Age (years) 23.8±7.6 24.7±8.6 23.8± 7.7 25.6±8.3
Systolic BP (mmHg) 129.1±21.0 128.8±20.7 128.7±21.4 130.3±18.2
Diastolic BP (mmHg) 78.5±14.1 77.6±14.6 78.5 ± 14.4 76.6 ±13.0
eGFR (ml/min/1.73m2) 100.2±50.1 92.4±38.5 100.7±50.8 87.7±38.3
Urinary protein (g/d) 2.0±2.4 2.6±2.6 2.0±2.5 2.6±2.8
Proportion sclerosed glomeruli (%) 0.1±0.2 0.1±0.2 0.1±0.2 0.1±0.2
Proportion with glomerular crescents (%) 1.5±6.0 1.1±3.1 1.4±5.8 1.9±5.6
Grade of interstitial fibrosis b 0.8±0.7 1.0±0.7 0.8±0.7 0.8±0.8
Grade of tubular atrophy c 0.7±0.8 0.9±1.0 0.7±0.8 0.8±0.9
Pre-eclampsia in the mother (%) 7 (1.7) 3 (6.3) 3 (0.7) 6 (13.3) a
N (%) birth weight <10th percentile (LBW) 0% 100% (by def.) 18(4.4) 24 (53.3) a
N (%) gestational age <37 weeks 8 (2.0) 19 (41.3) 24 (5.9) 3 (6.7)
N (%) birth weight <10th percentile for gestational age (SGA) 19 (4.7) 26 (56.5) 0% 100% (by def.)
a p<0.001
b Grade of interstitial fibrosis was categorized as mild, moderate or severe if the fibrosis involved <25%, 25–50% or more than 50% of the cortical area
respectively.
c Grade of tubular atrophy was categorized as mild, moderate or severe if the tubular atrophy involved <25%, 25–50% or more than 50% of the cortical
area respectively.
doi:10.1371/journal.pone.0153819.t001
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Single versus multiple adverse birth-weight related outcomes and risk of
ESRD
From the analyses presented in Tables 2 and 3, SGA was associated with slightly higher hazard
ratios for ESRD as compared to LBW. Preterm birth was on the other hand not associated with
Table 2. Risk of ESRD according to whether the IgAN patients had LBW, SGA or preterm birth, separate analyses for male and female, Norway
1967–2013.
Unadjusted model Adjusted modela
N total N ESRD HR (95% CI) p-value HR (95% CI) p-value
Total 471 74
Not LBW 423 62 1.0 (ref) 1.0 (ref)
LBW 48 12 2.0 (1.1–3.7) 0.03 1.4 (0.69–2.7) 0.4
Not SGA 405 57 1.0 (ref) 1.0 (ref)
SGA 45 11 2.2 (1.1–4.2) 0.02 1.4 (0.67–3.0) 0.4
Not Preterm 423 62 1.0 (ref) 1.0 (ref)
Preterm 27 6 1.5 (0.65–3.5) 0.3 0.95 (0.38–2.4) 0.9
Male
Not LBW 298 48 1.0 (ref) 1.0 (ref)
LBW 34 10 2.2 (1.1–4.4) 0.02 1.1 (0.52–2.4) 0.8
Not SGA 283 43 1.0 (ref) 1.0 (ref)
SGA 32 10 2.7 (1.4–5.5) 0.005 1.4 (0.64–3.2) 0.4
Not Preterm 295 48 1.0 (ref) 1.0 (ref)
Preterm 20 5 1.6 (0.64–4.0) 0.3 0.74 (0.26–2.1) 0.7
Female
Not LBW 125 14 1.0 (ref) 1.0 (ref)
LBW 14 2 1.3 (0.30–5.8) 0.7 1.4 (0.32–6.4) 0.6
Not SGA 122 14 1.0 (ref) 1.0 (ref)
SGA 13 1 0.8 (0.10–5.9) 0.8 0.8 (0.11–6.3) 0.9
Not Preterm 128 14 1.0 (ref) 1.0 (ref)
Preterm 7 1 1.1 (0.14–8.4) 0.9 1.0 (0.14–8.0) 1.0
aAdjusted for estimated Glomerular Filtration in 3 categories (i.e. > 60, 30–59 and < 30 ml/min respectively).
doi:10.1371/journal.pone.0153819.t002
Fig 1. Cumulative Probability of ESRD in patients with IgAN according to whether or not the patient had LBW.
doi:10.1371/journal.pone.0153819.g001
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Fig 2. Cumulative Probability of ESRD in patients with IgAN according to whether or not the patient had SGA.
doi:10.1371/journal.pone.0153819.g002
Table 3. Risk of ESRD among IgAN patients analysed at different percentile cut-offs for birth weight and birth weight for gestational age.
Unadjusted Adjusted a
N total N ESRD HR (CI) p-value HR (CI) p-value
Birth weight percentileb
25th perc 352 52 1.0(ref) 1.0 (ref)
<25th perc 119 22 1.3(0.76–2.1) 0.4 0.96(0.57–1.6) 0.9
20th perc 377 53 1.0 (ref) 1.0 (ref)
<20th perc 94 21 1.7(1.0–2.8) 0.05 1.2(0.69–2.0) 0.5
15th perc 401 58 1.0 (ref) 1.0 (ref)
<15th perc 70 16 1.8(1.0–3.2) 0.04 1.1 (0.58–2.0) 0.8
10th percc 423 62 1.0 (ref) 1.0 (ref)
<10th percc 48 12 2.0(1.1–3.7) 0.03 1.4(0.69–2.7) 0.4
7.5th perc 437 66 1.0 (ref) 1.0 (ref)
<7.5th perc 34 8 1.6(0.78–3.4) 0.2 1.1(0.48–2.6) 0.8
Birth weight for gestational age percentiled
 25th perc 336 49 1.0 (ref) 1.0(ref)
< 25th perc 114 19 1.2(0.68–2.0) 0.6 1.0(0.57–1.8) 1.0
 20th perc 360 52 1.0(ref) 1.0(ref)
< 20th perc 90 16 1.3 (0.76–2.3) 0.3 1.2(0.66–2.2) 0.5
 15th perc 383 56 1.0 (ref) 1.0(ref)
<15th perc 67 12 1.3 (0.69–2.4) 0.4 1.0(0.5–2.1) 1.0
10th percc 405 57 1.0 (ref) 1.0(ref)
<10th percc 45 11 2.2 (1.1–4.2) 0.02 1.4(0.67–3.0) 0.4
7.5th perc 416 59 1.0 (ref) 1.0 (ref)
<7.5th perc 34 9 2.5(1.2–5.1) 0.01 1.4(0.62–3.4) 0.4
aAdjusted for estimated Glomerular Filtration in 3 categories (i.e. > 60, 30–59 and < 30 ml/min respectively)
b for males, birth weight percentile < 25th, <20th, <15th, <10th and <7.5th percentile was defined as < 3.2325 kg, 3.1680 kg, 3.0695 kg, 2.9300 kg and
2.8597 kg respectively; for females, corresponding birth weights were 3.0500 kg, 2.9600 kg, 2.9100 kg, 2.6900 kg and 2.6400 kg respectively.
c Identical analysis as in Table 2, included for completeness.
d for males, birth weight for gestational age z–scores corresponding to < 25th, <20th, <15th, <10th and <7.5th were -0.7400,-0.8680,-1.1120,-1.2900 and
-1.5000 respectively. For females, corresponding z-scores were -0.9600,-1.1620, -1.3360, -1.5280 and -1.6620.
doi:10.1371/journal.pone.0153819.t003
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development of ESRD. To explore this further, we analyzed the combined effect of SGA and/or
LBW on the risk of developing ESRD (Table 4). In these analyses, patients who were either
SGA or LBW had no increased risk, but patients who were both SGA and LBW had a signifi-
cantly higher HR of 3.2 (1.5–6.8), p = 0.002 for the total cohort and a HR of 3.6 (1.6–8.2),
p = 0.02 for males (Table 4), the number of patients in subgroups were however low and confi-
dence intervals were wide.
Repeated analyses testing the combined effect of preterm birth and/or LBW showed that
LBW in preterm birth was not associated with higher hazard ratio of ESRD than LBW in term
birth [2.2(0.97–5.2) vs 2.1 (0.89–4.5)]. Identical analysis for the combined effect of preterm
birth and/or SGA did on the other hand show a stronger effect of SGA in preterm as compared
to term births (10.8 (2.6–45) vs 1.9 (0.93–3.1) (results not shown).
Discussion
In this comprehensive, registry-based study, we have shown that LBW was significantly associ-
ated with increased risk of progression to ESRD in IgAN. Having been born SGA, indicating
intrauterine growth restriction, was also associated with ESRD. These effects were significant
in the total cohort and in males, but we could not find evidence of increased risk in females.
Further analyses showed that patients with combined LBW and SGA have significantly
increased risk of developing ESRD as compared to patients with only one of the markers. After
adjustments for eGFR at time of diagnosis, the birth weight related variables were no longer
associated with progression to ESRD.
As described in the introduction, previous studies have shown associations between birth-
weight related variables and increased risk for all-cause ESRD in the total population [8,36,37].
In a previous Norwegian study, LBW was also associated with higher risk of ESRD due to glo-
merular disease, of which IgAN was an important group [8]. The present study has added the
information that LBW is a risk marker for progressive IgAN. This has to our knowledge never
previously been shown in IgAN, although a previous study showed that children with IgAN
Table 4. Risk of ESRD among IgAN patients stratified by LBW, SGA or the combination of these, (gender-wise).
Unadjusted model Adjusted modela
N total N ESRD HR (95% CI) p-value HR (95% CI)a p-value
Total
Not SGA or LBW 385 53 1.0 (ref) 1.0 (ref)
SGA, not LBW 19 3 1.3 (0.39–4.0) 0.7 0.74(0.18–3.0) 0.7
Not SGA, LBW 20 4 1.4 (0.51–3.9) 0.5 1.0 (0.36–2.8) 1.0
SGA and LBW 26 8 3.2 (1.5–6.8) 0.002 2.0 (0.87–4.8) 0.1
Male
Not SGA or LBW 270 40 1.0 (ref) 1.0 (ref)
SGA, not LBW 13 3 1.9 (0.57–6.0) 0.3 0.89 (0.21–3.7) 0.9
Not SGA, LBW 13 3 1.6 (0.50–5.3) 0.4 0.74 (0.22–2.5) 0.6
SGA and LBW 19 7 3.6 (1.6–8.2) 0.002 1.8 (0.70–4.6) 0.2
Female
Not SGA or LBW 115 13 1.0 (ref) 1.0 (ref)
SGA, not LBW 6 0 0.0 1.0 0.0 1.0
Not SGA, LBW 7 1 1.0 (0.13–7.8) 1.0 1.0 (0.14–8.1) 1.0
SGA and LBW 7 1 1.8 (0.23–13.6) 0.6 2.2(0.28–17.1) 0.5
a Adjusted for estimated Glomerular Filtration in 3 categories (i.e. > 60, 30–59 and < 30 ml/min respectively)
doi:10.1371/journal.pone.0153819.t004
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who were born with LBW had significantly higher proportion of sclerotic glomeruli than chil-
dren with normal birth weight [27]. Another study indicated higher rates of relapsing minimal
change disease in children born with LBW[38]. LBW is the most used marker of intrauterine
growth retardation and has been shown to be associated with a reduced number of enlarged
glomeruli [2,3,39], salt sensitivity of blood pressure [40,41], higher blood pressure [42,43],
microalbuminuria and low glomerular filtration rate [11], all markers that could be associated
with higher risk of progressive renal failure [44,45]. Taken together, this suggests that LBW
may be strongly associated with increased rates of progressive renal disease.
During nephrogenesis, week 9 to 36 in utero, the number of formed nephrons correlates
with increase in fetal weight. LBW is the most accessible marker of adverse intrauterine envi-
ronment [1], birth weight may however be affected both by duration of gestation and rate of
fetal growth [46]. A previous histomorphometric study deduces that about 260,000 nephrons
are formed for every 1kg increase in fetal weight in utero [3]. It can also be calculated that
about twenty thousand nephrons are formed per week of gestation, and of these about 60% are
formed during the third trimester [47]. Prematurity leads to 'oligonephropathy' with quantita-
tive and qualitative alteration of nephron formation [48] and also LBW and SGA are associated
with reduced nephron numbers in humans [1]. SGA may be a better marker of intrauterine
growth restriction as LBW at short gestational age may be physiologically normal. In a previous
Norwegian study that investigated risk of all cause ESRD, LBW was associated with slightly
higher hazard ratio of ESRD than SGA[8].
In this current study, SGA was on the other hand associated with slightly higher hazard
ratio than LBW. The finding that SGA might be a strong risk marker have been indicated by
previous studies demonstrating increased risk for development of renal disease and hyperten-
sion [49,50], lower renal drug clearance [12], having smaller kidneys at birth and impaired kid-
ney growth in early childhood [51]. An important observation was however that patients born
with both LBW and SGA had much higher risk for developing ESRD than those born with
only SGA or LBW, patients with only one marker did not have a statistically significant
increased risk. In this study, we did not observe any significant difference in clinicopathological
characteristics when we compared those who had combined LBW and SGA to those who had
neither of them. Zidar et al on the other hand found higher mean percentage of sclerotic glo-
meruli among those with previous IUGR [52]. Our study indicate that future studies of intra-
uterine growth restriction and adult renal disease need to investigate both the birth weight as
well as the birth weight in relation to gestational age. Patients with both LBW and SGA and
renal disease may also need closer follow-up.
In the paragraph above we discussed how a lower number of nephrons could represent a
lower reserve capacity and predispose to progressive renal disease. It is however also possible
that intrauterine nutritional imbalances could program immunological function or risk that
may persist throughout life [53]. Previous studies have suggested that early life perturbations of
the immune system may be associated with lifelong increased risk for autoimmune and allergic
diseases as well as chronic inflammatory conditions such as diabetes, cardiovascular diseases,
metabolic syndrome and cancer [54–56]. Furthermore, prolonged, impairment of cell-medi-
ated immunity is more common among LBW infants [57]. In relation to kidney diseases, Hoy
et al found that low birth weight in the aborigines in Australia predisposed to post-infectious
glomerulonephritis [58], this could however also have been explained by higher rates of pov-
erty which highly correlates with both malnutrition and increased susceptibility to infectious
diseases. Using the same definition of LBW as in a previous population-based study by us, we
found that 11.9% of our IgAN patients would be categorised as LBW [59]. This is slightly
higher than the 9.9% in the previous study[59], but this was not statistically significant. Thus,
IgAN patients seem to have the same prevalence of LBW as the population and this argues
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against LBW being a significant risk marker for development of IgAN through immunological
mechanisms.
Adjusted analysis showed that the association between LBW/SGA and progression to ESRD
was lost after adjustments for eGFR. The most likely explanation for this is that eGFR is a
much stronger risk factor for ESRD than LBW or SGA. It might however also imply that
reduced GFR itself may be a consequence of being born SGA or LBW [12]. In the present
study, males born with SGA had lower eGFR at time of diagnosis than males without SGA. It is
still unclear whether LBW or SGA should be taken into consideration when treating patients
with IgAN or planning studies of IgAN, but we would argue that more knowledge is needed
and that there could be important effects that could be uncovered in larger or more targeted
studies.
We observed that the association between LBW and increased risk of ESRD was significant
and strong in males but not in females. Globally, gender distribution in IgA nephropathy varies
widely in different populations with more preponderance towards male gender ranging from a
male: female ratio of less than 2:1 in Japan [60] to 6:1 in the in the Western countries being
highest in the in Northern Europe [61–63]. Recent registry-based data on IgAN in Japan[64]
and Korea[65] have shown no appreciable gender difference as contrasted to data from the
Norwegian Kidney Biopsy Register in which male comprised of 74% of all IgAN cases[25].
This wide range however may in part reflect the observed difference in subjective clinical indi-
cations and thresholds of performing a kidney biopsy among nephrologists in different coun-
tries, or other genetic/environmental differences between different areas of the world that have
no clinical explanation so far[66]. The statistical analysis in our analyses may however be polar-
ized towards showing stronger effect in males due to compromised statistical power in females.
Previous studies however, have suggested that females may be protected against the detrimen-
tal effects of LBW on progressive renal disease [67–69], although renal clearance studies could
not show a clear effect modification on the associations between LBW and reduced renal func-
tion [12,70,71]. In the present study, it is possible that the observed gender difference could be
attributed to smaller sample size and fewer endpoints for females, thus increasing risk of Type
2 statistical error and should thus be interpreted with caution.
The strengths of the present study are that the study is registry based with complete national
inclusion, have prospective registration of birth weight related variables, investigates a clinically
useful condition (IgAN) and has a clinically relevant and reliable end point (ESRD). A weak-
ness was that data on death was not available for the cohort and patients could not be censored
for death. Another weakness is that ESRD is a rare outcome and usually takes considerable
time to develop, number of patients with endpoints were therefore low in some subgroups. As
an inclusion criterion of the study was being born after 1967, we were only able to include a rel-
atively young cohort of IgAN patients (mean age at biopsy was 24 years). Previous studies have
shown that for IgAN patients younger than 60 years and elevated serum creatinine level> 2.0
mg/dl, young age correlated with poor prognosis[72] [73].
Another limitation is that we did not have information regarding the treatment the patients
received, most patients were however treated by nephrologists and received standard interna-
tional care with angiotensin inhibition for those with either high blood pressure or proteinuria
since the 1990’s, steroid treatment have been increasingly used since the early 2000’s for those
with proteinuria above 1 gr/24h and preserved kidney function after a trial period with angio-
tensin inhibition.
In conclusion, the present study has shown that birth-weight related variables were associ-
ated with risk for developing ESRD, the association was stronger in male patients who were the
predominant gender of this cohort (mirroring global trends). Both LBW and SGA were impor-
tant risk markers, but the combination of these were especially important. Our results support
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the Brenner hypothesis. Future studies should investigate further the importance of SGA vs
LBW and whether these markers are associated with altered renal morphology and risk of pro-
gression to ESRD also in other kidney diseases.
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